According to new data from SullivanCotter, compensation in the United States is up more than 20% in the last five years for interventional cardiology, electrophysiology, general cardiology and vascular surgery. This points to workforce that is getting more competitive over time, one expert told Cardiovascular Business.
The new software from Chicago-based Tempus AI was designed to identify signs of moderate or severe MR. This is the company's second FDA clearance in the last two months.
Readmission rates are getting lower over time among patients treated at nonprofit hospitals. At for-profit facilities, meanwhile, readmission rates have stayed relatively unchanged.
The Heart Failure Society of America has released a new comprehensive look at HF clinics in the United States. The report includes more than 300 programs that serve approximately 626,000 patients.
“Our analyses could not fully ascribe the effects of semaglutide on cardiovascular disease to known risk factors with any certainty,” one researcher said after exploring years of data. "These results suggest that semaglutide should be considered as a cardiovascular disease reduction drug and not just as a weight loss drug."
"I want to be safe, I want to get the vessel open and I don’t want to spend a long time doing it," cardiologist William C. Dixon, MD, explains. "IVL helps me achieve all of those things.”
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
